Comparing the bioequivalence and safety of liraglutide in healthy Chinese subjects: an open, single-dose, randomized, repeated, two-sequence, two-cycle phase I clinical trial

References

• Chen HJ, Ko CY, Xu JH, et al. Alleviative effect of Ruellia tuberosa L. on insulin resistance and abnormal lipid accumulation in TNF-alpha-treated FL83B mouse hepatocytes. Evid Based Complement Alternat Med. 2021;2021:9967910.
   PubMedGoogle Scholar
• Toft-Nielsen MB, Madsbad S, Holst JJ. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care. 1999 Jul;22(7):1137–1143.
   PubMed Web of Science ®Google Scholar
• Diabetes facts & figures. [ updated 2020 Feb 12]. Available from: https://www.idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html
   Google Scholar
• National Diabetes Information Clearinghouse. National diabetes statistics. 2007. [cited 2021 Aug 1]. Available from: http://diabetes.niddk.nih.gov/dm/pubs/statistics/
   Google Scholar
• Beverly EA, Osowik F. Clinically significant depressive symptoms and high diabetes distress in adults with type 1 and type 2 diabetes in Appalachian Ohio. J Osteopath Med. 2021 Jul 15;121(10):813–824.
   PubMedGoogle Scholar
• Meyer-Bothling U, Meyer-Bothling O, Pinney M. A real-world single-centre study of patients with diabetic Macular Oedema who wore a home-use sleep mask (Noctura 400) for one year. J Ophthalmol. 2021;2021:6612126.
   PubMedGoogle Scholar
• King GL, Park K, Li Q. Selective insulin resistance and the development of cardiovascular diseases in diabetes: the 2015 Edwin Bierman Award lecture. Diabetes. 2016 Jun;65(6):1462–1471.
   PubMedGoogle Scholar
• Guo L, Zheng J, Pan Q, et al. Changes in direct medical cost and medications for managing diabetes in Beijing, China, 2016 to 2018: electronic insurance data analysis. Ann Fam Med. 2021 Jul-Aug;19(4):332–341.
   PubMedGoogle Scholar
• Li X, Xu Z, Ji L, et al. Direct medical costs for patients with type 2 diabetes in 16 tertiary hospitals in urban China: a multicenter prospective cohort study. J Diabetes Investig. 2019 Mar;10(2):539–551.
   PubMedGoogle Scholar
• Lingvay I, Desouza CV, Lalic KS, et al. A 26-week randomized controlled trial of semaglutide once daily versus liraglutide and placebo in patients with type 2 diabetes suboptimally controlled on diet and exercise with or without metformin. Diabetes Care. 2018 Sep;41(9):1926–1937.
   PubMed Web of Science ®Google Scholar
• Orskov C, Holst JJ, Nielsen OV. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology. 1988 Oct;123(4):2009–2013.
   PubMed Web of Science ®Google Scholar
• Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012 Dec;8(12):728–742.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Meier JJ. Management of endocrine disease: are all GLP-1 agonists equal in the treatment of type 2 diabetes? Eur J Endocrinol. 2019 Dec;181(6):R211–R234.
   PubMed Web of Science ®Google Scholar
• Green BD, Gault VA, O’Harte FP, et al. Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents. Curr Pharm Des. 2004;10(29):3651–3662.
   PubMedGoogle Scholar
• Velazquez A, Apovian CM. Updates on obesity pharmacotherapy. Ann N Y Acad Sci. 2018 Jan;1411(1):106–119.
   PubMedGoogle Scholar
• Bizino MB, Jazet IM, Westenberg JJM, et al. Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial. Cardiovasc Diabetol. 2019 Apr 30;18(1):55.
   PubMed Web of Science ®Google Scholar
• Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009 Mar;26(3):268–278.
   PubMed Web of Science ®Google Scholar
• Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009 Jan;32(1):84–90.
   PubMed Web of Science ®Google Scholar
• Tilinca MC, Tiuca RA, Burlacu A, et al. A 2021 update on the use of liraglutide in the modern treatment of ‘Diabesity’: a narrative review. Medicina (Kaunas). 2021 Jun 29;57(7). doi:10.3390/medicina57070669.
   PubMedGoogle Scholar
• Cheang JY, Moyle PM. Glucagon-like peptide-1 (GLP-1)-based therapeutics: current status and future opportunities beyond type 2 diabetes. ChemMedChem. 2018 Apr 6;13(7):662–671.
   PubMed Web of Science ®Google Scholar
• Nielsen R, Jorsal A, Tougaard RS, et al. The impact of the glucagon-like peptide-1 receptor agonist liraglutide on natriuretic peptides in heart failure patients with reduced ejection fraction with and without type 2 diabetes. Diabetes Obes Metab. 2020 Nov;22(11):2141–2150.
   PubMedGoogle Scholar
• Alvarez-Villalobos NA, Trevino-Alvarez AM, Gonzalez-Gonzalez JG. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016 Nov 3;375(18):1797–1798.
   PubMedGoogle Scholar
• FDA Victoza label. [ cited 2021 Aug 5]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022341s004lbl.pdf
   Google Scholar
• Patel S, Abreu M, Tumyan A, et al. Effect of medication adherence on clinical outcomes in type 2 diabetes: analysis of the SIMPLE study. BMJ Open Diabetes Res Care. 2019;7(1):e000761.
   PubMedGoogle Scholar
• Yamada Y, Katagiri H, Hamamoto Y, et al. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial. Lancet Diabetes Endocrinol. 2020 May;8(5):377–391.
   PubMed Web of Science ®Google Scholar
• Gallwitz B. GLP-1 receptor agonists in type 2 diabetes and beyond - new insights 2015. Eur Endocrinol. 2015 Apr;11(1):21–25.
   PubMedGoogle Scholar
• Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019 Jul 6;394(10192):39–50.
   PubMed Web of Science ®Google Scholar
• Chang AM, Jakobsen G, Sturis J, et al. The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes. 2003 Jul;52(7):1786–1791.
   PubMed Web of Science ®Google Scholar
• Li M, Yang Y, Jiang D, et al. Efficacy and safety of liraglutide versus sitagliptin both in combination with metformin in patients with type 2 diabetes: a systematic review and meta-analysis. Medicine (Baltimore). 2017 Sep;96(39):e8161.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Muus Ghorbani ML, Kreiner E, et al. Effects of liraglutide compared with placebo on events of acute gallbladder or biliary disease in patients with type 2 diabetes at high risk for cardiovascular events in the LEADER randomized trial. Diabetes Care. 2019 Oct;42(10):1912–1920.
   PubMed Web of Science ®Google Scholar
• Li Y, Qi L, Bai H, et al. Pharmacokinetics and bioequivalence of rasagiline tablets in Chinese healthy subjects under fasting and fed conditions: an open, randomized, single-dose, double-cycle, two-sequence, crossover trial. Front Pharmacol. 2020;11:571747.
   PubMedGoogle Scholar
• Davit BM, Chen ML, Conner DP, et al. Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products by the US Food and Drug Administration. AAPS J. 2012 Dec;14(4):915–924.
   PubMed Web of Science ®Google Scholar
• European Medicine Agency. 2010. Guideline on the investigation of bioequivalence. [cited 2021 Aug 23]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf
   Google Scholar
• Guidance for industry bioavailability and bioequivalence studies submitted in NDAs or INDs-general considerations [ cited 2021 Aug 15]. Available from: https://www.fda.gov/media/88254/download
   Google Scholar
• Damholt B, Golor G, Wierich W, et al. An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide. J Clin Pharmacol. 2006 Jun;46(6):635–641.
   PubMedGoogle Scholar
• Madsbad S. Liraglutide Effect and Action in Diabetes (LEAD) trial. Expert Rev Endocrinol Metab. 2009 Mar;4(2):119–129.
   PubMedGoogle Scholar
• Jiang J, Zhang J, Jacobsen LV, et al. The pharmacokinetics, pharmacodynamics, and tolerability of liraglutide, a once-daily human GLP-1 analogue, after multiple subcutaneous administration in healthy Chinese male subjects. J Clin Pharmacol. 2011 Dec;51(12):1620–1627.
   PubMedGoogle Scholar
• Mai G, Fan L, Li M, et al. A randomized phase 1 pharmacokinetic study comparing the potential biosimilar LRG201902 with liraglutide (Victoza((R))) in healthy male subjects. Front Pharmacol. 2020;11:610880.
   PubMedGoogle Scholar
• Blonde L, Russell-Jones D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. Diabetes Obes Metab. 2009 Dec;11(Suppl 3):26–34.
   PubMed Web of Science ®Google Scholar